Judge Mulls BioXcel's Duty To Tell Investors Of FDA Troubles

By Brian Steele · June 24, 2024, 9:39 PM EDT

A Connecticut federal judge wondered Monday if executives at the artificial intelligence-driven drugmaker BioXcel Therapeutics Inc. had an opportunity to correct problems that government regulators identified with a key clinical trial...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Case Information

Case Title

Hills et al v. BioXcel Therapeutics, Inc. et al

Case Number

Court

Connecticut

Nature of Suit

Securities/Commodities

Date Filed

July 07, 2023

Recent Articles By Brian

November 08, 2024
Conn. AG Building Abortion Rights 'Firewall' With Firms' Help
October 30, 2024
Conn. Justices Doubt Fertility Doc Suit Is For 'Wrongful Life'
October 28, 2024
Transgender Inmate's Suit Meets Skeptical 2nd Circ. Judge
October 28, 2024
Conn. Healthcare Co.'s $1.5M Data Breach Deal Gets Final OK
October 25, 2024
Pharmacy Must Pay $39.2M In Conn. Kickback Case
October 18, 2024
AGs Slam 4th Circ. Bid To Restore NC Abortion Drug Limits
October 04, 2024
Healthcare Co.'s Workers Get Cert. In OT Pay Row
September 26, 2024
Split 2nd Circ. Backs 8 Years For Conn. COVID Money Scam
September 05, 2024
ER Doctors End Surprise Billing Battle With Harvard Pilgrim
September 03, 2024
Scientist Says Yale Medical School Ruined $28M 'Life's Work'